RBC’s Pharma Picks: Lilly Leads Momentum, AbbVie Anchors Value List
RBC has released its preferred pharmaceutical stock selections, splitting recommendations between momentum and value strategies. Eli Lilly is flagged as the top momentum choice with a $1,250 price target driven by its GLP-1 franchise and the potential launch of oral orforglipron. AbbVie is RBC’s top value pick at a $260 target, backed by immunology…